Atea Pharmaceuticals, Inc. has reported positive topline results from the Phase 3 C-BEYOND trial, showing that its once-daily bemnifosbuvir and ruzasvir combination was statistically non-inferior to Gilead Sciences’ Epclusa in treatment-naïve adults with chronic hepatitis C. The experimental regimen produced a 93.9% sustained virologic response rate across patients with and without compensated cirrhosis, compared with 94.8% for Epclusa. Its main potential advantage emerged among patients without cirrhosis, who received eight weeks of bemnifosbuvir and ruzasvir instead of the standard 12-week Epclusa course.
The results support Atea’s effort to develop a shorter pan-genotypic treatment, but they do not yet establish regulatory approval or superiority over existing direct-acting antivirals. C-BEYOND produced topline findings from North America, while the fully enrolled C-FORWARD Phase 3 trial must still confirm performance across the broader genotype distribution found outside the United States and Canada.
Eight-week bemnifosbuvir and ruzasvir matched a 12-week standard in patients without cirrhosis
C-BEYOND enrolled 905 patients in its modified intent-to-treat analysis at approximately 120 sites across the United States and Canada. Participants were treatment-naïve adults with chronic hepatitis C, including patients without cirrhosis and those with compensated cirrhosis. The study compared the fixed-dose bemnifosbuvir and ruzasvir combination directly with sofosbuvir and velpatasvir, the active ingredients in Epclusa.
Across the complete modified intent-to-treat population, 93.9% of patients receiving Atea’s combination achieved sustained virologic response, compared with 94.8% of patients receiving Epclusa. Sustained virologic response measured 12 weeks after treatment is generally regarded as a hepatitis C cure because the virus is no longer detectable in the patient’s blood at that point. The confidence interval for the difference remained within the trial’s prespecified 5% non-inferiority margin, allowing C-BEYOND to meet its primary endpoint.
The most commercially and clinically relevant subgroup included 721 patients without cirrhosis. Those assigned to bemnifosbuvir and ruzasvir received treatment for eight weeks and achieved a 93.5% sustained virologic response rate. Patients receiving Epclusa were treated for 12 weeks and achieved a 94.6% response rate. Atea therefore produced a cure-rate difference of approximately one percentage point while shortening treatment by four weeks.
Among 184 patients with compensated cirrhosis, both regimens were administered for 12 weeks and each achieved a 95.4% sustained virologic response rate. This result suggests that the experimental combination can maintain efficacy in patients with more advanced liver disease, but its treatment-duration advantage presently applies to the non-cirrhotic population.
Atea estimates that approximately 80% to 90% of people living with hepatitis C in the United States do not have cirrhosis. That makes the eight-week regimen relevant to a substantial proportion of potential patients, although the estimate comes from the company and does not indicate how many people will be diagnosed, linked to care or eligible under a future approved label.
Why non-inferiority matters even though Epclusa produced a slightly higher overall cure rate
C-BEYOND was designed as a non-inferiority trial rather than a superiority study. The objective was not to prove that bemnifosbuvir and ruzasvir cured more patients than Epclusa. It was to demonstrate that any reduction in efficacy remained within an agreed margin while potentially offering advantages in treatment duration, administration or drug interactions.
The overall cure rate was numerically lower with Atea’s regimen, at 93.9% compared with 94.8%. The non-cirrhotic subgroup showed a similar pattern, at 93.5% compared with 94.6%. Those differences did not prevent the trial from succeeding because the statistical analysis showed that the experimental combination remained within the prespecified non-inferiority boundary.
This distinction should remain clear in communicating the results. Bemnifosbuvir and ruzasvir matched the established comparator under the trial’s statistical design, but the topline data do not demonstrate superior cure rates. Its differentiated value depends primarily on achieving comparable outcomes with an eight-week course for most patients.
Epclusa is an established pan-genotypic treatment indicated for hepatitis C genotypes 1 through 6. Its approved regimen is generally one tablet daily for 12 weeks in patients without cirrhosis or with compensated cirrhosis. The product can be taken with or without food and has accumulated extensive clinical and commercial experience since its first approval in 2016.
Reducing treatment by four weeks could improve convenience and lower the number of tablets required. It may also reduce the period during which patients must remain adherent, which could be helpful in populations facing unstable housing, substance-use disorders, limited healthcare access or other barriers to completing therapy.
A shorter regimen does not automatically produce better real-world outcomes. Modern hepatitis C treatments are already highly effective and generally well tolerated, so Atea will need to show that the eight-week duration produces meaningful improvements in completion, access, cost or healthcare-system efficiency.
Safety and drug-interaction data could shape the regimen’s value beyond treatment duration
Atea reported that bemnifosbuvir and ruzasvir were generally safe and well tolerated in C-BEYOND. The company said there were no drug-related serious adverse events and no drug-related early treatment discontinuations. Virologic failure rates were described as low and comparable between the treatment groups.
The announcement did not provide complete adverse-event tables, laboratory findings or detailed discontinuation rates. Those data will be required to determine whether the regimen offers a meaningful tolerability advantage or introduces safety issues that are not visible in the topline summary.
Atea has also emphasized the combination’s potential for a low risk of drug-drug interactions and administration with or without food. These features could become important because many people with hepatitis C take medications for HIV, opioid-use disorder, cardiovascular conditions, psychiatric illness or other chronic diseases.
Drug-interaction claims will ultimately depend on the final regulatory review and prescribing information. The company must show that its proposed profile holds across the medicines commonly used by patients in routine practice rather than relying only on theoretical or early pharmacology advantages.
B9emnifosbuvir is a nucleotide polymerase inhibitor targeting the hepatitis C NS5B polymerase, while ruzasvir inhibits the viral NS5A protein. Combining agents that attack different stages of viral replication is intended to produce potent antiviral activity and reduce the likelihood of resistance.
The trial included the genotypes most commonly encountered in North America, but the company has not yet released detailed cure rates by genotype, baseline viral load, demographic group or other clinically relevant categories. Those analyses will help determine whether the overall result is consistent across patient populations or influenced by stronger performance in particular subgroups.
C-FORWARD remains crucial before Atea can define a global filing strategy
Atea’s global Phase 3 program includes two similarly designed studies. C-BEYOND covered the United States and Canada, while C-FORWARD has enrolled more than 880 treatment-naïve patients at approximately 120 sites in 17 countries outside North America.
C-FORWARD is expected to include a wider distribution of hepatitis C genotypes, including variants that occur less frequently in North America. Its results will therefore be important for determining whether the regimen can support a broad pan-genotypic label across multiple regions.
Atea expects topline C-FORWARD results in early 2027. The company plans to present detailed findings from the global program at future medical conferences and submit them for publication in peer-reviewed journals.
A successful second trial would allow Atea to assemble a more complete regulatory package. Failure to reproduce the C-BEYOND result, a weaker outcome in less common genotypes or an unexpected safety signal could complicate the filing strategy even after the North American study met its endpoints.
The open-label design is another consideration. Both patients and investigators knew which treatment was assigned, although the primary endpoint was based on an objective laboratory measurement of viral RNA. This reduces some forms of bias but does not eliminate the value of independent review and complete publication.
Hepatitis C remains a major global health challenge despite the availability of curative medicines. Atea estimates that approximately 50 million people worldwide live with chronic infection, including as many as four million in the United States. Untreated infection can lead to cirrhosis, liver failure and liver cancer, while gaps in diagnosis and linkage to treatment remain major barriers to elimination.
The C-BEYOND result gives Atea a credible late-stage asset with a clearly defined differentiator. Bemnifosbuvir and ruzasvir did not outperform Epclusa on cure rate, but the combination maintained high efficacy while reducing treatment to eight weeks for patients without cirrhosis.
Its eventual clinical role will depend on whether the shorter course, interaction profile and administration flexibility are considered valuable enough to justify switching from deeply established therapies. C-FORWARD, full safety disclosure and regulatory discussions will determine whether the positive North American result becomes the foundation of a competitive new hepatitis C treatment.
